Bradley Foster & Sargent Inc. CT Reduces Position in Edwards Lifesciences Co. (NYSE:EW)

Bradley Foster & Sargent Inc. CT lessened its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 3.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,365 shares of the medical research company’s stock after selling 479 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in Edwards Lifesciences were worth $1,063,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Wellington Management Group LLP grew its position in Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the last quarter. State Street Corp grew its position in Edwards Lifesciences by 1.0% during the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after purchasing an additional 256,538 shares during the last quarter. Geode Capital Management LLC grew its position in Edwards Lifesciences by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after purchasing an additional 284,918 shares during the last quarter. Fisher Asset Management LLC lifted its stake in Edwards Lifesciences by 9.8% during the 3rd quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock valued at $599,078,000 after acquiring an additional 806,705 shares during the period. Finally, Jennison Associates LLC acquired a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $555,939,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at $2,315,301.36. This represents a 26.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now directly owns 60,372 shares of the company’s stock, valued at $4,613,628.24. The trade was a 8.68 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,489 shares of company stock valued at $2,002,829 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have commented on EW shares. Morgan Stanley lifted their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Sanford C. Bernstein upgraded shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Daiwa America cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Piper Sandler lifted their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Finally, The Goldman Sachs Group lifted their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and a consensus price target of $79.95.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $73.25 on Friday. The firm has a market cap of $43.20 billion, a PE ratio of 10.51, a PEG ratio of 4.82 and a beta of 1.10. The firm has a fifty day moving average of $72.85 and a 200 day moving average of $70.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.